title: Introduction: fusidic acid enters the United States.
authors.affiliation: Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. rmoeller@bidmc.harvard.edu
authors.forename: Robert C
authors.initials: RC
authors.lastname: Moellering
authors.forename: G Ralph
authors.initials: GR
authors.lastname: Corey
authors.forename: M Lindsay
authors.initials: ML
authors.lastname: Grayson
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005672:Fusidic Acid / Q000627:therapeutic use*; D006095:Gram-Positive Cocci / Q000187:drug effects; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D005672:Fusidic Acid